What is Post-Exposure Prophylaxis?

Post-exposure prophylaxis (PEP) refers to preventive medical treatment initiated after exposure to a pathogen to prevent infection or the progression of the disease. Typically used in the context of HIV exposure, PEP involves a course of antiretroviral drugs administered to an individual who may have been recently exposed to the virus, with the intent of reducing the risk of HIV infection. The treatment is most effective when started as soon as possible, ideally within hours of exposure, and must be continued for a specified duration.

DoxyPEP: A New Horizon in Prophylaxis

Doxycycline, a member of the tetracycline antibiotics group, has been traditionally used to treat bacterial infections such as STIs, pneumonia, acne, and Lyme disease. The advent of DoxyPEP has opened new horizons, allowing for the prevention of infections after exposure, particularly in the realms of sexually transmitted infections (STIs) and vector-borne diseases.

One notable pilot study involved 30 MSM (men who have sex with men) living with HIV, who had experienced two or more episodes of syphilis since their HIV diagnosis. These participants were randomly assigned to receive doxycycline 100 mg for 48 weeks or undergo a financial incentive-based behavioral intervention. Remarkably, the study showcased a 73% reduction in any bacterial STI across any site, with no significant changes in sexual behavior. This promising result has paved the way for additional studies on doxycycline prophylaxis, with several now in progress or in the planning stages.

The strongest evidence came from the DoxyPEP randomized controlled trial (Luetkemeyer et al., NEJM 2023), which enrolled over 500 MSM and transgender women. Participants who took 200 mg of doxycycline within 72 hours of condomless sex saw a 66% reduction in chlamydia and syphilis infections compared to the control group. Gonorrhea reduction was more modest at around 55%, likely due to existing doxycycline resistance in N. gonorrhoeae. Based on these results, the CDC issued interim clinical guidance in 2023 recommending DoxyPEP for MSM and transgender women at increased risk of bacterial STIs.

Dosage & Side Effects

Patients are advised to take 200mg (two 100mg tablets) within 72 hours of exposure. While preliminary results are encouraging, it's pivotal to understand that there remains a risk of contracting STDs. Hence, subsequent STD testing is essential for confirmation.

Like any medication, Doxycycline can have side effects. Some common ones include:

• Loss of appetite
• Nausea and vomiting
• Diarrhea
• Rash
• Sensitivity to the sun
• Hives
• Temporary discoloring of teeth

Thus it's imperative to consult with a healthcare professional before commencing treatment and to discontinue use once the risk of exposure has passed.

Conclusion

DoxyPEP is a promising post-exposure strategy for reducing bacterial STI acquisition, particularly chlamydia and syphilis. It is not a replacement for regular STI testing — rather, it is an additional tool for people at higher risk. If you are sexually active and concerned about STI exposure, regular testing remains essential whether or not you use DoxyPEP.

Disclaimer: This blog post is intended for educational purposes only and should not be taken as medical advice. Always consult your healthcare provider for personal health concerns.